C4 Therapeutics Advances Cemsidomide into Later-Stage Trials with $297M Cash Runway
Event summary
- First patient dosed in Phase 2 MOMENTUM trial for cemsidomide in multiple myeloma, targeting accelerated approval.
- Phase 1b trial of cemsidomide in combination with Pfizer’s elranatamab expected to initiate in Q2 2026.
- Second degrader designed for Biogen entered clinical development for autoimmune diseases.
- Cash position strengthened to $297.1M, providing runway to end of 2028.
The big picture
C4 Therapeutics is positioning cemsidomide as a potential best-in-class IKZF1/3 degrader, leveraging strategic partnerships and a robust cash position to advance its targeted protein degradation platform. The company’s focus on later-stage trials and expanded indications reflects broader industry trends toward precision oncology and immune-directed therapies. With a runway extending to 2028, C4T aims to solidify its role as a fully integrated biopharmaceutical player.
What we're watching
- Clinical Progress
- Whether cemsidomide can maintain its differentiated safety and efficacy profile in later-stage trials.
- Regulatory Pathway
- The pace at which the MOMENTUM trial progresses toward potential accelerated approval.
- Financial Flexibility
- How C4 Therapeutics will allocate its $297M cash position to advance its pipeline and sustain operations.
Related topics